InvestorsObserver
Sign Up Login

ATNM Actinium Pharmaceuticals Inc

$5.83 $-0.02 (-0.34%)
Add to Watchlist Compare
Overall

ATNM Stock Analysis Overview

What this means: Actinium Pharmaceuticals Inc (ATNM) gets an Overall Rank of 62, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. ATNM's 62 means that it ranks higher than 62% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

ATNM Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

ATNM Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

ATNM Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

ATNM Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

ATNM Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

ATNM Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

ATNM Stock Analysis Overview

What this means: Actinium Pharmaceuticals Inc (ATNM) gets an Overall Rank of 62, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. ATNM's 62 means that it ranks higher than 62% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full ATNM report

ATNM Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

ATNM Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

ATNM Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

ATNM Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

ATNM Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

ATNM Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Actinium Pharmaceuticals Inc (ATNM) Analyst Forecast

ATNM Price, Volume, Earnings, and Dividend Date

  • Last Price $5.83
  • Previous Close $5.85
  • Change $-0.02
  • Open $5.81
  • Volume 42,813
  • Avg. Volume (100-day) 606,138
  • Market Cap 146,826,533
  • Days Range 5.8 - 5.91
  • 52-week Range 4.41 - 10.3
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E —
  • EPS —
  • Earnings Date 08/11/22
  • Sector Healthcare
  • Industry Biotechnology
  • Avg. Analyst Rec. Premium
  • Beta 1.026
  • PEG Ratio —

Actinium Pharmaceuticals Inc (ATNM) Company Description

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its most advanced products are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Actinium Pharmaceuticals Inc (ATNM) Stock Chart

View Interactive ATNM chart

My Watchlists

Follow Your Favorite Stocks

Top Stocks in Biotechnology

Company Price
Axsome Thera (AXSM) (AXSM) $42.43
Arcutis Biotherapeutics Inc (ARQT) (ARQT) $25.99
Savara Inc (SVRA) (SVRA) $1.64
Pliant Therapeutics Inc (PLRX) (PLRX) $19.89
Trevi Therapeutics Inc (TRVI) (TRVI) $3.75
G1 Therapeutics Inc (GTHX) (GTHX) $12.81
Verona Pharma Plc ADR (VRNA) (VRNA) $12.82
Concert Pharmaceutic (CNCE) (CNCE) $7.03
Dyne Therapeutics Inc (DYN) (DYN) $12.26
Geron Corp (GERN) (GERN) $2.19